Use and Changes in Glucagon-Like Peptide-1 Medicine Use Among Adults in the United States, 2025
Updated
Abstract
Approximately 10% of U.S. adults reported taking a GLP-1 medication in the past year.
- One in five GLP-1 users reported using a compounded version of the medication, which is not FDA-reviewed.
- Nearly two in five GLP-1 users adjusted their medication use, often due to cost and availability issues.
- Modifications in GLP-1 medication use were particularly prevalent among younger adults.
- The widespread use of GLP-1 medications indicates their growing role in treating chronic diseases.
- Understanding real-world adjustments in medication use is important for assessing safety and effectiveness.
Simplified